NCT07080125View on ClinicalTrials.gov

A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis

Active, not recruitingOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

June 16, 2023

Primary Completion Date

December 31, 2033

Study Completion Date

December 31, 2033

Conditions
Interstitial Lung DiseasesSystemic Sclerosis Associated Interstitial Lung Disease
Interventions
DRUG

Ofev®

Ofev®

Trial Locations (1)

4051

EUSTAR Registry, Basel

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY